ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aclaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.48+0.20 (+6.10%)
Close on Oct 19, 2026
- Market cap
- $496.72M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
73.3%+52.5 pts over 5 years
Operating margin
-975.9%−190.5 pts over 5 years
Net margin
-829.6%−42.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -58.2% | -35.9% | +3.8% | – | |
| Gross profit | -64.0% | -39.4% | +33.6% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -36.7% | -94.9% | -50.2% | |
| Return on assets | -35.6% | -60.3% | -34.1% | |
| Current ratio | 22.27 | 3.87 | 3.36 | |
| Capex to revenue | – | 7.0% | 1.4% | |
| Diluted shares | 21M | 43M | 123M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Aclaris Therapeutics generated $265.21M from operations and spent $2.45M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$265.21M
Used
$2.45M
Capital expenditure$2.45M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-829.6%
×Asset turnover0.04×
×Equity multiplier1.47×
=Return on equity, FY2025-50.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -829.6% | 0.04× | 1.47× | -50.2% |
| FY2024 | -705.5% | 0.09× | 1.34× | -84.5% |
| FY2023 | -283.1% | 0.14× | 1.27× | -49.9% |
| FY2022 | -292.1% | 0.12× | 1.28× | -44.0% |
| FY2021 | -1344.0% | 0.04× | 1.37× | -77.3% |
| FY2020 | -787.0% | 0.08× | 1.57× | -94.9% |
| FY2019 | -3817.2% | 0.02× | 1.31× | -113.2% |
| FY2018 | -2158.0% | 0.02× | 1.18× | -60.3% |
| FY2017 | -4071.5% | 0.01× | 1.06× | -34.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$64.92M
- Cash generatingOperating cash flow above zero-$47.11M
- Return on assets improvedROA up on the prior year-66.9% → -29.5%
- Earnings backed by cashOperating cash flow above net income-$47.11M vs -$64.92M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.99 → 3.36
- No dilutionShare count did not rise77M → 123M
- Gross margin improvedGross margin up on the prior year85.09% → 73.28%
- More efficientAsset turnover rose0.09 → 0.04